Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 188241 | GSK-626616 | 1025821-33-3 | >98% |  |
| GSK 626616 is a YAK3/DYRK3 kinase inhibitor. It is a chemoprotective agent for the po | ||||
| 187182 | GT 949 | 460330-27-2 | >98% |  |
| GT 949 is a selective EAAT2 positive allosteric modulator (EC50 = 0.26 nM). Enhances | ||||
| 187163 | GSK-J4 free base | 1373423-53-0 | >98% |  |
| GSK-J4 is a cell permeable, potent and selective histone demethylase. | ||||
| 187122 | Gefapixant | 1015787-98-0 | 98% |  |
| Gefapixant, also known as AF-219 or MK-7264, is a P2X3 receptor antagonist. Gefapixan | ||||
| 185313 | GLL398 | 2077980-83-5 | >98% |  |
| GLL398 is an Oral Selective Estrogen Receptor Downregulator. | ||||
| 185311 | Glecaprevir | 1365970-03-1 | >98% |  |
| Glecaprevir, also known as ABT-493 and A-1282576, is a NS 3/4A inhibitor potentially | ||||
| 185292 | GW843682X | 660868-91-7 | >98% |  |
| GW843682X is a selective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase | ||||
| 18595 | GNE-7915 | 1351761-44-8 | >98% |  |
| GNE-7915 is a potent LRRK2 kinase inhibitor. | ||||
| 1842811 | GLPG1837 | 1654725-02-6 | >98% |  |
| GLPG-1837, also known as ABBV-974, is a novel cystic fibrosis transmembrane conductan | ||||
| 184175 | GC376 sodium | 1416992-39-6 | >98% |  |
| GC376 is a 3CLpro inhibitor (3C-like protease inhibitor). | ||||
| 18494 | GNF-6231 | 1243245-18-2 | >98% |  |
| GNF-6231 is a potent, selective, and orally bioavailable Porcupine inhibitor that blo | ||||
| 184316 | GSK-3326595 | 1616392-22-3 | >98% |  |
| GSK-3326595, also known as EPZ015938, is an orally active, potent and selective inhib | ||||
| 18428 | GIBH-130 | 1252608-59-5 | >98% | |
| GIBH-130是一种神经炎症抑制剂。 | ||||
| 17101621 | GSK872 | 1346546-69-7 | >98% |  |
| GSK872 is a a receptor interacting protein kinase-3 (RIP3) inhibitor. GSK872 inhibits | ||||
| 1791316 | GSK2881078 | 1539314-06-1 | 98.0% |  |
| GSK-2881078 is a selective androgen receptor modulator potentially for the treatment | ||||
| 1791116 | GJ-103 sodium | 1459687-96-7 | 98.0% |  |
| GJ103 sodium salt is an active analog of the read-through compound GJ072. | ||||
| 1791115 | GJ-103 free acid | 1459687-89-8 | 98.0% |  |
| GJ-103 is an active analog of the read-through compound GJ072. Chemical-induced read | ||||
| 1791112 | 10074-G5 | 413611-93-5 | 98.0% |  |
| 10074-G5 is a c-Myc/Max interaction inhibitor. 10074-G5, similarly to 10058-F4 (#F368 | ||||
| 1791110 | GW0742 | 317318-84-6 | 98.0% |  |
| GW0742, also known as GW610742 and GW0742X is a PPARδ/β agonist. GW0742 Induces Ear | ||||
| 17919 | Givinostat HCl | 199657-29-9 | 98.0% |  |
| Givinostat or gavinostat, aslo known as ITF2357, is a potent and orally active histon | ||||
| 1783018 | Grazoprevir hydrate | 1350462-55-3 | 98.0% | |
| Grazoprevir, also known as MK5172, is a drug approved for the treatment of hepatitis | ||||
| 1781006 | GNE-3511 | 1496581-76-0 | 98.0% |  |
| GNE-3511 is a potent and selective dual leucine zipper kinase (DLK, MAP3K12) inhibito | ||||
| 178914 | GSK2193874 | 1336960-13-4 | 98.0% |  |
| GSK2193874 was identified as a selective, orally active TRPV4 blocker that inhibits C | ||||
| 178912 | GW4869 | 6823-69-4 | 98.0% |  |
| GW4869 (dihydrochloride hydrate) is a cell permeable, selective inhibitor of N-SMase | ||||
| 178911 | GSK2982772 | 1622848-92-3 | 98.0% |  |
| GSK2982772 is an ATP competitive eceptor-interacting protein-1 (RIP1) kinase inhibit | ||||
| 178901 | GSK180736A (GSK180736) | 817194-38-0 | 98.0% | -cas-817194-38-0.png) |
| GSK180736A is potent and selective inhibitor of GRK2 with an IC50 of 0.77 M25 and >10 | ||||
| 2017883 | GSK2269557 | 1254036-77-5 | 98.0% |  |
| GSK2269557,also known as GSK-2269557, is a potent and selective PI3K inhibitor. | ||||
| 2017881 | GDC-0326 | 1282514-88-8 | 98.0% |  |
| GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kina | ||||
| 20178215 | GSK-1521498 | 1007573-18-3 | 98.0% |  |
| GSK-1521498 is a novel -Opioid receptor antagonist. It has been shown to attenuate re | ||||
| 2017821 | GSK321 | 1816331-63-1 | 98.0% |  |
| GSK321 is a potent and selective IDH1 mutant inhibitor. GSK321 potently inhibited int | ||||